Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-targeted ligand-drug conjugate
- Development stage
- Preclinical
- Lead developer
- Izvarino Pharma Group
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
PSMA-targeted ligand-drug conjugate refers to a class of targeted therapeutic agents designed to deliver cytotoxic payloads directly to prostate cancer cells by binding to prostate-specific membrane antigen (PSMA). Izvarino Pharma, in collaboration with Russian academic institutions (including Lomonosov Moscow State University, Moscow Institute of Physics and Technology, and National University of Science and Technology MISiS), has developed several preclinical candidates within this platform. These include small-molecule conjugates linking PSMA-targeting ligands to various therapeutic payloads, such as docetaxel (PSMA-DOC), abiraterone (PSMA-Abi), and monomethyl auristatin E (MMAE), as well as diagnostic/imaging agents (such as PSMA-SulfoCy7 and PSMA-SulfoCy5). These conjugates aim to improve antitumor efficacy while reducing systemic toxicity compared to free chemotherapeutic agents.
- Other names
- PSMA-targeted ligand-diagnostic conjugate
02
Targets
TOP2A (DNA topoisomerase II)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PSMA-targeted ligand-drug conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-targeted ligand-drug conjugate.